Long COVID has mystified the medical community for years, making it a tough condition to diagnose, let alone treat. However, a growing body of research has found more information on what may be behind ...
3don MSN
Rallybio shares successful early-stage results for rare disease drug; new trial set for late 2026
Rallybio Corporation RLYB on Tuesday shared results from its Phase 1 confirmatory pharmacokinetic/pharmacodynamic (PK/PD) ...
Changes to serum proteins could be behind the debilitating condition known as long COVID. The findings, published in the journal Science, could pave the way for diagnosing and treating the disease.
Share on Pinterest A study offers new clues on why long COVID persists in some individuals. krisanapong detraphiphat/Getty Images Despite the debilitating nature of long COVID, there is an absence of ...
Most people infected with the SARS-CoV-2 virus recover after the acute illness. However, a significant proportion of infected individuals develop long-lasting symptoms with a wide range of ...
Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...
In a study, blocking the immune system complement protein C3 was shown to reduce MS disease severity in older mice but not in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results